Noveome Biotherapeutics, Inc.
ST266 secretome biologic containing bioactive proteins for neuroprotection and tissue healing
- Sector
- Biotech
- Headquarters
- PITTSBURGH, PA
- Latest Form D
- $6.8M, Aug 2026
- Total capital
- $41.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $33M
- 6 Form D · last Aug 2026
- 2 months since last filing
- Federal contracts
- $8.5M
- 1 award · Defense
- Rank in Biotech#62 of 4373
- Granted patents
- 4
- 30 pending · first 2017
- Rank in peer group#35 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$6.8M
- Private capital raisedForm D · SEC · 5th filing$20.7M
- Private capital raisedForm D · SEC · 4th filing$870K
- Private capital raisedForm D · SEC · 3rd filing$2.4M
- Private capital raisedForm D · SEC · 2nd filing$1.7M
- Private capital raisedForm D · SEC · 1st filing$571K
- Federal contractDefense · Cellular Combat Wound Initiative$8.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
5months
from Noveome Biotherapeutics, Inc.’s first federal award to its first private round.
- First federal award · Feb 2012
- Defense · $8.5M
- First Form D · Jul 2012
- $571K · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#163 · top 42%
- Granted patents#35 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- A. Clarke AtwellExecutive Officer, DirectorNamed in SEC Form D filings
- Craig NemiroffDirectorNamed in SEC Form D filings
- Donald WagnerDirectorNamed in SEC Form D filings
- Eric KellerDirectorNamed in SEC Form D filings
- Gretchen KraemerExecutive OfficerNamed in SEC Form D filings
- Houman HemmatiDirectorNamed in SEC Form D filings
Show all 14 people
- John McArthurDirectorNamed in SEC Form D filings
- Michael KaufmanDirectorNamed in SEC Form D filings
- Patrick WelchDirectorNamed in SEC Form D filings
- Patric WelchExecutive Officer, DirectorNamed in SEC Form D filings
- Robert LangerDirectorNamed in SEC Form D filings
- Ronald PoropatichDirectorNamed in SEC Form D filings
- Terence GoldenDirectorNamed in SEC Form D filings
- William GoldenExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 34- PendingTreatment Of Systemic Inflammatory ResponsesUSPTOApplication 18908448
- GrantedTreatment of Systemic Inflammatory ResponsesUSPTOUS 12,121,546
- PendingSecretome Fractions And Uses ThereofUSPTOApplication 18036815
Show all 34 patent records
- Treatment Of Systemic Inflammatory ResponsesJan 23, 2025 · Application 18908448Pending
- Treatment of Systemic Inflammatory ResponsesOct 22, 2024 · US 12,121,546Granted
- Secretome Fractions And Uses ThereofFeb 29, 2024 · Application 18036815Pending
- Modulating Ischemic InjuryFeb 3, 2022 · Application 17494690Pending
- Use of ST266 to Treat Severe Systemic Inflammation and Post-Acute COVID-19 SyndromeSep 23, 2021 · Application 17197580Pending
- Treatment of Diseases and Conditions Caused by Increased Vascular PermeabilityAug 20, 2020 · Application 16370923Pending
- Methods for Reducing the Extent of Light-induced Tissue Inflammation and InjuryMay 14, 2020 · Application 16747736Pending
- Novel methods for delivering therapeutics agents to the eye via the nasal passagesMar 19, 2020 · Application 16690197Pending
- Methods for treating nervous system injury and diseaseMay 14, 2019 · US 10,286,015Granted
- Modulating Ischemic InjuryOct 11, 2018 · Application 15990614Pending
- Treatment of diseases and conditions caused by increased vascular permeabilitySep 27, 2018 · Application 15990718Pending
- Methods for Reducing the Extent of Light-induced Tissue Inflammation and InjurySep 27, 2018 · Application 15464523Pending
- Novel methods for delivering therapeutic agents to the eye via nasal passagesJul 26, 2018 · Application 15927327Pending
- Treatment of diseases and conditions caused by increased vascular permeabilityMay 29, 2018 · US 9,980,987Granted
- Interproximal Drug Delivery DeviceOct 31, 2017 · US 9,802,010Granted
- Methods for treating ocular contusion and blunt injury and traumatic injury of the optic nerveJul 27, 2017 · Application 15480993Pending
- Methods for preventing or treating optic neuritisJul 20, 2017 · Application 15477559Pending
- Methods for preventing and/or treating nasal polyps and rhinosinusitisMay 18, 2017 · Application 15362951Pending
- Novel cell-derived compositionFeb 9, 2017 · Application 15289362Pending
- Methods for treating hidradenitis suppurativaDec 22, 2016 · Application 15254222Pending
- Methods for Modulating Skin InflammationDec 22, 2016 · Application 15254345Pending
- Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal PassagesDec 15, 2016 · Application 15180855Pending
- Methods for treating blepharitisNov 10, 2016 · Application 15202087Pending
- Cellular Factor-Containing Solution Compositions for the Treatment of Rhinovirus Infection and SymptomsOct 13, 2016 · Application 15092019Pending
- Methods for treating ophthalmic disorders, diseases and injuriesAug 4, 2016 · Application 15095231Pending
- Methods for treating cartilage disorders, diseases and injuriesAug 4, 2016 · Application 15095367Pending
- Immortalization Of Amnion-derived Multipotent Progenitor Cell And Uses ThereofApplication 19168512Pending
- Use of ST266 To Treatment Severe Systemic Inflammatory ResponsesApplication 63064495Pending
- Secretome Fractions and Uses ThereofApplication 63114060Pending
- Use Of ST266 To Treat Severe Systemic Inflammation And Post-acute COVID-19 SyndromeApplication PCTUS2021021675Pending
- Secretome Fractions And Uses ThereofApplication PCTUS2021059521Pending
- Immortalization Of Amnion-derived Multipotent Progenitor Cell And Uses ThereofApplication PCTUS2024021177Pending
- Novel Methods For Delivering Therapeutic Agents To The Eye Via Nasal PassagesApplication PCTUS2016037217Pending
- Use of ST266 as a Multi-Targeted Anti-Cytokine Storm Treatment for COVID-19Application 62991962Pending
Related companies, and why
- Ceramedix Holding, LLCSimilar federal contract value in Biotech · $10.2M in contracts
- SACHI BIOWORKS, INC.Similar federal contract value in Biotech · $9.8M in contracts
- INNOVATION PATHWAYS, LLCSimilar federal contract value in Biotech · $9.2M in contracts
- Ionis PharmaceuticalsSimilar federal contract value in Biotech · $8.4M in contracts
- ARISAN THERAPEUTICS INCSimilar federal contract value in Biotech · $8.3M in contracts
- BNB PLUS CORP.Similar federal contract value in Biotech · $8M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .